Pancreatic Adenocarcinoma
275
57
91
96
Key Insights
Highlights
Success Rate
74% trial completion
Published Results
41 trials with published results (15%)
Research Maturity
96 completed trials (35% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
12.0%
33 terminated out of 275 trials
74.4%
-12.1% vs benchmark
4%
12 trials in Phase 3/4
43%
41 of 96 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 96 completed trials
Clinical Trials (275)
The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma
EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Resistance Training Intervention to Improve Physical Function in Patients With Pancreatic Cancer Receiving Combination Chemotherapy or Have Undergone Surgery, PancStrength Study
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
To Evaluate the Feasibility and Safety of Combining Surgery (Pancreatectomy and Cytoreduction) With HIPEC for Treating Pancreatic Cancer With Peritoneal Involvement.
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma